A Real-world, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib Versus Apremilast in Adults With Plaque Psoriasis - North American Region
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Have been diagnosed with plaque psoriasis by a dermatologist
• Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
• Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes
Locations
United States
Massachusetts
Local Institution
RECRUITING
Waltham
Contact Information
Primary
BMS Study Connect Contact Center www.BMSStudyConnect.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain the NCT# and Site #.
Time Frame
Start Date: 2022-09-30
Estimated Completion Date: 2027-12-10
Participants
Target number of participants: 1500
Treatments
Cohort 1
Participants that have initiated deucravacitinib
Cohort 2
Participants that have initiated apremilast
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb